Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

被引：11

作者：

Benza, Raymond L. ^{[1
]}

Langleben, David ^{[2
]}

Hemnes, Anna R. ^{[3
]}

Noordegraaf, Anton Vonk ^{[4
]}

Rosenkranz, Stephan ^{[5
]}

Thenappan, Thenappan ^{[6
]}

Hassoun, Paul M. ^{[7
]}

Preston, Ioana R. ^{[8
]}

Ghio, Stefano ^{[9
]}

Badagliacca, Roberto ^{[10
]}

Vizza, Carmine D. ^{[10
]}

Lang, Irene M. ^{[11
]}

Meier, Christian ^{[12
]}

Gruenig, Ekkehard ^{[13
]}

机构：

[1] Ohio State Univ Wexner Med Ctr, Dept Med, Columbus, OH 43210 USA

[2] McGill Univ, Jewish Gen Hosp, Ctr Pulm Vasc Dis, Div Cardiol, Montreal, PQ, Canada

[3] Vanderbilt Univ Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA

[4] Vrije Univ Amsterdam Med Ctr, Pulm Dis, Amsterdam, Netherlands

[5] Cologne Univ Heart Ctr, Dept Cardiol, Cologne, Germany

[6] Univ Minnesota, Dept Med, Cardiovasc Div, Minneapolis, MN USA

[7] Johns Hopkins Univ, Pulm & Crit Care Med, Baltimore, MD USA

[8] Tufts Med Ctr, Pulm Crit Care & Sleep Med Div, Boston, MA USA

[9] Fdn IRCCS Policlin San Matteo, Div Cardiol, Pavia, Italy

[10] Sapienza Univ, Dept Cardiol, Rome, Italy

[11] Med Univ Vienna, Allgemeines Krankenhaus, Dept Internal Medicine 2, Div Cardiol, Vienna, Austria

[12] Global Med Affairs, Bayer AG, Berlin, Germany

[13] Heidelberg Univ Hosp, Ctr Pulm Hypertens, Thoraxklin Heidelberg gGmbH, Heidelberg, Germany

来源：

EUROPEAN RESPIRATORY REVIEW | 2022年 / 31卷 / 166期

关键词：

SOLUBLE GUANYLATE-CYCLASE; ENDOTHELIN-RECEPTOR ANTAGONIST; RIGHT HEART; EXERCISE CAPACITY; BOSENTAN TREATMENT; PROGNOSTIC VALUE; SILDENAFIL; PARAMETERS; MANAGEMENT; SURVIVAL;

D O I：

10.1183/16000617.0061-2022

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH.

引用

页数：12

共 50 条

[11] Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Marra, Alberto M.
Egenlauf, Benjamin
Ehlken, Nicola
Fischer, Christine
Eichstaedt, Christina
Nagel, Christian
Bossone, Eduardo
Cittadini, Antonio
Halank, Michael
Gall, Henning
Olsson, Karen M.
Lange, Tobias J.
Gruenig, Ekkehard
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 195 : 19 - 26
[12] Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Ghofrani, Hossein-Ardeschir
D'Armini, Andrea M.
Grimminger, Friedrich
Hoeper, Marius M.
Jansa, Pavel
Kim, Nick H.
Mayer, Eckhard
Simonneau, Gerald
Wilkins, Martin R.
Fritsch, Arno
Neuser, Dieter
Weimann, Gerrit
Wang, Chen
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (04) : 319 - 329
[13] Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Saleh, Soundos
Becker, Corina
Frey, Reiner
Mueck, Wolfgang
PULMONARY CIRCULATION, 2016, 6 : S86 - S96
[14] Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center
Sulica R.
Fenton R.
Cefali F.
Cardiology and Therapy, 2015, 4 (2) : 209 - 218
[15] Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
Kim, N.
EUROPEAN RESPIRATORY REVIEW, 2010, 19 (115) : 68 - 71
[16] Riociguat in the Treatment of Pulmonary Arterial Hypertension
Jerjes-Sanchez, Carlos
Glenn-Valdez, Hector
Zayas, Nayeli
Cueto-Robledo, Guillermo
Bonola, Liliana
Pech-Alonso, Baltazar
Ramirez, Alicia
Flores-Puente, Fernando
Garcia-Aguilar, Humberto
Espitia-Hernandez, Guadalupe
Prisciliano Montes, Guillermo
Pulido, Tomas
ARCHIVES OF MEDICAL RESEARCH, 2022, 53 (04) : 352 - 358
[17] Support Experienced by Patients Living with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Ivarsson, Bodil
Ekmehag, Bjorn
Sjoberg, Trygve
HEART LUNG AND CIRCULATION, 2016, 25 (01) : 35 - 40
[18] Developments in pulmonary arterial hypertension-targeted therapy for chronic thromboembolic pulmonary hypertension
Hadinnapola, Charaka
Pepke-Zaba, Joanna
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (05) : 559 - 569
[19] Differences in Ventilatory Inefficiency Between Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Zhai, Zhenguo
Murphy, Kevin
Tighe, Hannah
Wang, Chen
Wilkins, Martin R.
Gibbs, J. Simon R.
Howard, Luke S.
CHEST, 2011, 140 (05) : 1284 - 1291
[20] The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension
DeSouza, Shilpa A.
Preston, Ioana R.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2015, 13 (05) : 467 - 476

← 1 2 3 4 5 →